Single Drop Whole Blood Diagnostics: Portable Biomedical Sensor for Cardiac Troponin I Detection

2018 ◽  
Vol 90 (4) ◽  
pp. 2867-2874 ◽  
Author(s):  
Indu Sarangadharan ◽  
Shin-Li Wang ◽  
Revathi Sukesan ◽  
Pei-chi Chen ◽  
Tze-Yu Dai ◽  
...  
Keyword(s):  
Whole Blood ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Single Drop ◽  
Biomedical Sensor

scholarly journals Evaluation of Innotrac Aio! Second-Generation Cardiac Troponin I Assay: The Main Characteristics for Routine Clinical Use

2006 ◽  
Vol 2006 ◽  
pp. 1-7 ◽  
Author(s):  
P. Hedberg ◽  
J. Valkama ◽  
E. Suvanto ◽  
S. Pikkujämsä ◽  
K. Ylitalo ◽  
...  
Keyword(s):  
Rheumatoid Factor ◽  
Whole Blood ◽  
Cardiac Troponin ◽  
First Generation ◽  
Second Generation ◽  
Troponin I ◽  
Reference Group ◽  
Rapid Test ◽  
Cardiac Troponin I ◽  
The Stability

The availability of a simple, sensitive, and rapid test using whole blood to facilitate processing and to reduce the turnaround time could improve the management of patients presenting with chest pain. The aim of this study was an evaluation of the Innotrac Aio! second-generation cardiac troponin I (cTnI) assay. The Innotrac Aio! second-generation cTnI assay was compared with the Abbott AxSYM first-generation cTnI, Beckman Access AccuTnI, and Innotrac Aio! first-generation cTnI assays. We studied serum samples from 15 patients with positive rheumatoid factor but with no indication of myocardial infarction (MI). Additionally, the stability of the sample with different matrices and the influence of hemodialysis on the cTnI concentration were evaluated. Within-assay CVs were 3.2%–10.9%, and between-assay precision ranged from 4.0% to 17.2% for cTnI. The functional sensitivity(CV=20%)and the concentration giving CV of 10% were approximated to be 0.02 and 0.04, respectively. The assay was found to be linear within the tested range of 0.063–111.6μg/L. The correlations between the second-generation Innotrac Aio!, Access, and AxSYM cTnI assays were good (rcoefficients 0.947–0.966), but involved differences in the measured concentrations, and the biases were highest with cTnI at low concentrations. The second-generation Innotrac Aio! cTnI assay was found to be superior to the first-generation assay with regard to precision in the low concentration range. The stability of the cTnI level was best in the serum, lithium-heparin plasma, and lithium-heparin whole blood samples (n=10, decrease<10%in 24 hours at+20°Cand at+4°C. There was no remarkable influence of hemodialysis on the cTnI release. False-positive cTnI values occurred in the presence of very high rheumatoid factor values, that is, over 3000 U/L. The 99th percentile of the apparently healthy reference group was≤0.03 μg/L. The results demonstrate the very good analytical performance of the second-generation Innotrac Aio! cTnI assay.

Cardiac Troponin I Microfluidic Chip Driven by Adaptive Pressure

2020 ◽  
Vol 12 (10) ◽  
pp. 1239-1247
Author(s):  
Xingshang Xu ◽  
Yuan Liu ◽  
Zhu Chen ◽  
Hui Chen ◽  
Yan Deng ◽  
...  
Keyword(s):  
Microfluidic Chip ◽  
Whole Blood ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Accurate Determination ◽  
Cardiac Troponin I ◽  
Chip Surface ◽  
Layer Composite ◽  
Novel Strategy ◽  
The Stability

To develop and design an adaptive microfluidic chip for accurate determination of cardiac troponin I (cTnI) in whole blood sample and explore the operating parameters of the chip in detecting cTnI, in order to provide a novel strategy for the detection of cTnI, cTnI microfluidic chip was prepared by injection moulding, and the improved polystyrene polymer was used as the chip substrate to construct a three-layer composite structure, namely the upper, middle, and lower layers. The antihuman troponin I antibody I/II was grafted onto the chip surface to construct the detection reaction zone using UV-induced production of surface-active free radicals. The stability of the chip preparation process, the running performance of the chip, and the analytical performance of the whole blood samples were investigated. It was shown that I adaptive pressure-driven microfluidic chip has the advantages of easy bonding, integration, and a simple and stable production process. In the actual detection and analysis, the chip has high selectivity for cTnI in whole blood, lower detection limit (0.054 ng/mL), and small difference between batches (RSD% 2.50%). Therefore, the chip is assumed to provide novel strategy for the assessment of myocardial infarction by detecting cTnI.

Evaluation of a Rapid Bedside Immunochromatographic Assay for Detection of Cardiac Troponin I in Whole Blood

2001 ◽  
Vol 39 (5) ◽  
Author(s):  
Franca Pagani ◽  
Cristina Serena ◽  
Carla Bosio ◽  
Claudio Cuccia ◽  
Mauro Panteghini
Keyword(s):  
Whole Blood ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Immunochromatographic Assay

Simultaneous Rapid Measurement of Whole Blood Myoglobin, Creatine Kinase MB, and Cardiac Troponin I by the Triage Cardiac Panel for Detection of Myocardial Infarction

1999 ◽  
Vol 45 (2) ◽  
pp. 199-205 ◽  
Author(s):  
Fred S Apple ◽  
Robert H Christenson ◽  
Roland Valdes ◽  
Alexander J Andriak ◽  
Amy Berg ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Creatine Kinase ◽  
Whole Blood ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Point Of Care ◽  
Cardiac Troponin I ◽  
Clinical Sensitivity ◽  
Creatine Kinase Mb ◽  
Acute Mi

Abstract This multicenter study evaluated the Biosite Triage® Cardiac Panel as a quantitative, multimarker, whole blood system for the detection of acute myocardial infarction (MI). Optimum cutoffs for the discrimination of acute MI (n = 192 patients, 59 with MI) as determined by ROC curve analyses were as follows: 0.4 μg/L for cardiac troponin I (cTnI); 4.3 μg/L for the creatine kinase MB isoenzyme (CK-MB); and 107 μg/L for myoglobin. The Triage Panel showed the following concordances for detection or rule-out of MI compared with established devices: cTnI &gt;89%; CK-MB &gt;81%; myoglobin &gt;69%. No significant differences were present between methods for the same marker. Diagnostic efficiencies demonstrated comparable sensitivities and specificities for the diagnosis of MI in patients presenting with symptoms compared with the Dade, Beckman, and Behring CK-MB, cTnI, and myoglobin assays; the ratio of sensitivity to specificity for each marker was as follows: cTnI, 98%:100%; CK-MB, 95%:91%; myoglobin, 81%:92%. The areas under the ROC curves for the Biosite myoglobin, CK-MB, and cTnI were 0.818, 0.905, and 0.970, respectively; the areas were significantly different, P &lt;0.05. In patients with skeletal muscle injury and renal disease, the Triage cTnI showed 94% and 100% specificity, respectively. The Triage panel offers clinicians a whole blood, point-of-care analysis of multiple cardiac markers that provides excellent clinical sensitivity and specificity for the detection of acute MI.

Evaluation of a novel high sensitivity cardiac troponin I assay with whole blood

2020 ◽  
Vol 508 ◽  
pp. 273-276
Author(s):  
Ya-hui Lin ◽  
Yang Li ◽  
Bao-man Su ◽  
Jin-suo Kang ◽  
Zhou Zhou
Keyword(s):  
Whole Blood ◽  
Cardiac Troponin ◽  
Troponin I ◽  
High Sensitivity ◽  
Cardiac Troponin I

scholarly journals Electrospun TiO2 nanofiber integrated lab-on-a-disc for ultrasensitive protein detection from whole blood

Lab on a Chip ◽  
2015 ◽  
Vol 15 (2) ◽  
pp. 478-485 ◽  
Author(s):  
Won Seok Lee ◽  
Vijaya Sunkara ◽  
Ja-Ryoung Han ◽  
Yang-Seok Park ◽  
Yoon-Kyoung Cho
Keyword(s):  
Whole Blood ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Protein Detection ◽  
Cardiac Troponin I ◽  
Tio2 Nanofiber

From 10 μL of whole blood, full steps of an ELISA are automated to achieve femtomolar- and picomolar-level detection for C-reactive proteins and cardiac troponin I, respectively.

scholarly journals Comparison of Cardiac Troponin I Measurements on Whole Blood and Plasma on the Stratus CS Analyzer and Comparison with AxSYM

2000 ◽  
Vol 46 (11) ◽  
pp. 1864-1866 ◽  
Author(s):  
Jean-Paul Chapelle ◽  
Marie-Claire Aldenhoff ◽  
Luc Pierard ◽  
Jacques Gielen
Keyword(s):  
Whole Blood ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiac Troponin I

scholarly journals Near-Bedside Whole-Blood Cardiac Troponin I Assay for Risk Assessment of Patients with Acute Coronary Syndromes

2002 ◽  
Vol 48 (10) ◽  
pp. 1784-1787 ◽  
Author(s):  
Fred S Apple ◽  
MaryAnn M Murakami ◽  
Robert L Jesse ◽  
M Andrew Levitt ◽  
Alan K Berger ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Whole Blood ◽  
Cardiac Troponin ◽  
Acute Coronary Syndromes ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Coronary Syndromes

scholarly journals Stability of Cardiac Troponin-I in Whole Blood and Plasma in Patients with Acute Myocardial Infarction

2021 ◽  
Vol 22 (1) ◽  
pp. 68-72
Author(s):  
Umut Karabulut ◽  
Dilay Karabulut ◽  
Pınar Kasapoğlu ◽  
Serkan Yazan ◽  
Mehmet Ertürk ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Whole Blood ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiac Troponin I

Clinical performance of a new point-of-care cardiac troponin I test

2018 ◽  
Vol 56 (8) ◽  
pp. 1336-1344 ◽  
Author(s):  
Michael Christ ◽  
Felicitas Geier ◽  
Sabine Blaschke ◽  
Evangelos Giannitsis ◽  
Mehdi Khellaf ◽  
...  
Keyword(s):  
Likelihood Ratio ◽  
Whole Blood ◽  
Predictive Value ◽  
Cardiac Troponin ◽  
Diagnostic Performance ◽  
Troponin I ◽  
Clinical Performance ◽  
Point Of Care ◽  
Cardiac Troponin I ◽  
Current Guidelines

Abstract Background: We evaluated the clinical performance of the Minicare cardiac troponin-I (cTnI), a new point-of-care (POC) cTnI test for the diagnosis of acute myocardial infarction (AMI) in a prospective, multicentre study (ISRCTN77371338). Methods: Of 474 patients (≥18 years) admitted to an emergency department (ED) or chest pain unit (CPU) with symptoms suggestive of acute coronary syndrome (ACS; ≤12 h from symptom onset), 465 were eligible. Minicare cTnI was tested immediately, 3 h and 6 h after presentation. AMI diagnoses were adjudicated independently based on current guidelines. Results: The diagnostic performance of the Minicare cTnI test at 3 h was similar for whole blood and in plasma: sensitivity 0.92 vs. 0.90; specificity 0.91 vs. 0.90; positive predictive value (PPV) 0.68 vs. 0.66; negative predictive value (NPV) 0.98 vs. 0.98; positive likelihood ratio (LR+) 10.18 vs. 9.41; negative likelihood ratio (LR–) 0.09 vs. 0.11. The optimal diagnostic performance was obtained at 3 h using cut-offs cTnI >43 ng/L plus cTnI change from admission ≥18.5 ng/L: sensitivity 0.90, specificity 0.96, PPV 0.81, NPV 0.98, and LR+ 21.54. The area under the receiver operating characteristics (ROC) curve for cTnI whole blood baseline value and absolute change after 3 h curve was 0.93. Conclusions: These data support the clinical usefulness of Minicare cTnI within a 0 h/3 h-blood sampling protocol supported by current guidelines for the evaluation of suspected ACS.

Sign in / Sign up

Export Citation Format

Share Document